Poly(methyl vinyl ether-alt-maleic anhydride) and Its Derivatives: From Polymer Synthesis to Advanced Biomedical...

Area of Science:

• Polymer Chemistry
• Biomaterials Science
• Nanotechnology

Background:

• Poly(methyl vinyl ether-alt-maleic anhydride) (PMVEMA) is a synthetic copolymer with notable biocompatibility, biodegradability, and bioadhesive characteristics.
• Its reactive anhydride groups allow for diverse chemical modifications and the creation of various functional derivatives.
• PMVEMA has garnered significant interest for its potential in advanced biomedical and pharmaceutical applications.

Purpose of the Study:

• To review and synthesize current knowledge on PMVEMA derivatives, physicochemical properties, and functionalization strategies.
• To highlight the relevance and applications of PMVEMA in the biomedical field.
• To identify key research trends and future directions for PMVEMA in medicine.

Main Methods:

• Comprehensive literature analysis across major scientific databases.
• Artificial intelligence-assisted text mining to identify research trends.
• Synthesis and characterization of PMVEMA derivatives and their performance evaluation in biomedical contexts.

Main Results:

• PMVEMA serves as a versatile platform for creating hydrogels, nanoparticles, and nanofibers with tunable properties.
• PMVEMA-based systems demonstrate enhanced mucosal adhesion, controlled drug release kinetics, and immunoadjuvant activity.
• These materials exhibit excellent biocompatibility both in vitro and in vivo, supporting applications in immunology, drug delivery, dentistry, and dermatology.

Conclusions:

• PMVEMA is a highly adaptable polymer with significant potential for diverse biomedical applications owing to its unique properties and derivatization capabilities.
• PMVEMA-based materials show promise for improved drug delivery, enhanced immunomodulation, and effective use in tissue engineering and regenerative medicine.
• Further research is essential to fully understand in vivo biodegradation pathways and to facilitate the clinical translation of PMVEMA-based technologies.